EP2124910A4 - Targeting of ews-fli1 as anti-tumor therapy - Google Patents

Targeting of ews-fli1 as anti-tumor therapy

Info

Publication number
EP2124910A4
EP2124910A4 EP07872364A EP07872364A EP2124910A4 EP 2124910 A4 EP2124910 A4 EP 2124910A4 EP 07872364 A EP07872364 A EP 07872364A EP 07872364 A EP07872364 A EP 07872364A EP 2124910 A4 EP2124910 A4 EP 2124910A4
Authority
EP
European Patent Office
Prior art keywords
fli1
ews
targeting
tumor therapy
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07872364A
Other languages
German (de)
French (fr)
Other versions
EP2124910A2 (en
Inventor
Jeffrey A Toretsky
Aykut Ueren
Milton Lang Brown
Yali Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Priority to EP13186704.6A priority Critical patent/EP2687206B1/en
Publication of EP2124910A2 publication Critical patent/EP2124910A2/en
Publication of EP2124910A4 publication Critical patent/EP2124910A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07872364A 2006-12-29 2007-12-28 Targeting of ews-fli1 as anti-tumor therapy Withdrawn EP2124910A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13186704.6A EP2687206B1 (en) 2006-12-29 2007-12-28 Targeting of EWS-FLI1 as anti-tumor therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87785606P 2006-12-29 2006-12-29
PCT/US2007/089118 WO2008083326A2 (en) 2006-12-29 2007-12-28 Targeting of ews-fli1 as anti-tumor therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13186704.6A Division EP2687206B1 (en) 2006-12-29 2007-12-28 Targeting of EWS-FLI1 as anti-tumor therapy

Publications (2)

Publication Number Publication Date
EP2124910A2 EP2124910A2 (en) 2009-12-02
EP2124910A4 true EP2124910A4 (en) 2012-02-15

Family

ID=39589226

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07872364A Withdrawn EP2124910A4 (en) 2006-12-29 2007-12-28 Targeting of ews-fli1 as anti-tumor therapy
EP13186704.6A Active EP2687206B1 (en) 2006-12-29 2007-12-28 Targeting of EWS-FLI1 as anti-tumor therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13186704.6A Active EP2687206B1 (en) 2006-12-29 2007-12-28 Targeting of EWS-FLI1 as anti-tumor therapy

Country Status (4)

Country Link
EP (2) EP2124910A4 (en)
AU (1) AU2007341977B2 (en)
CA (2) CA2711003C (en)
WO (1) WO2008083326A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
WO2010083505A1 (en) * 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
KR102145835B1 (en) 2012-04-12 2020-08-20 조지타운 유니버시티 Compositions for treating ewings sarcoma family of tumors
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
EP3204376B1 (en) 2014-10-09 2023-04-19 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
KR102375929B1 (en) * 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. Indoline analogs and uses thereof
MX2019000867A (en) 2016-07-29 2019-09-16 Oncternal Therapeutics Inc Uses of indolinone compounds.
CN108186630B (en) * 2017-12-18 2020-07-31 温州医科大学 Application of isatin analogue in preparation of antitumor drugs
CN110818611B (en) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 Indolone compounds, preparation method, pharmaceutical composition and application thereof
CN110845389A (en) * 2019-10-17 2020-02-28 袁健 Novel I-type topoisomerase inhibitor
US20220396839A1 (en) * 2019-11-12 2022-12-15 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
CN110950928A (en) * 2019-12-16 2020-04-03 武汉大学 Polypeptide for targeted diagnosis of Ewing sarcoma
CN114057626B (en) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) Indole-2, 3-dione derivative, preparation method thereof and anti-liver cancer drug for inhibiting RECQL4 specific expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288244A1 (en) * 2004-04-30 2005-12-29 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
WO2006117414A1 (en) * 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Non-human animal sarcoma model

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1155572C (en) * 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 Indole derivatives and its anticancer usage
US20030157486A1 (en) * 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288244A1 (en) * 2004-04-30 2005-12-29 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
WO2006117414A1 (en) * 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Non-human animal sarcoma model

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATEO-LOZANO SILVIA ET AL: "Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation.", ONCOGENE, vol. 22, no. 58, 18 December 2003 (2003-12-18), pages 9282 - 9287, XP002665931, ISSN: 0950-9232 *
TORETSKY JEFFREY A ET AL: "Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A", CANCER RESEARCH, vol. 66, no. 11, June 2006 (2006-06-01), pages 5574 - 5581, XP002665930, ISSN: 0008-5472 *
UREN A ET AL: "Recombinant EWS-FLI1 oncoprotein activates transcription", BIOCHEMISTRY 20041026 AMERICAN CHEMICAL SOCIETY US, vol. 43, no. 42, 26 October 2004 (2004-10-26), pages 13579 - 13589, XP002665929 *

Also Published As

Publication number Publication date
CA2711003C (en) 2017-02-21
CA2711003A1 (en) 2008-07-10
WO2008083326A2 (en) 2008-07-10
EP2687206A1 (en) 2014-01-22
EP2687206B1 (en) 2017-12-13
AU2007341977A1 (en) 2008-07-10
CA2953987A1 (en) 2008-07-10
AU2007341977B2 (en) 2013-05-23
EP2124910A2 (en) 2009-12-02
WO2008083326A3 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
EP2124910A4 (en) Targeting of ews-fli1 as anti-tumor therapy
IL248204A0 (en) Combination treatment of cd38-expressing tumors
EP2068864A4 (en) Therapeutic uses of urolithins
IL205307A0 (en) Targeting micrornas for the treatment of liver cancer
IL197315A0 (en) Treatment of cancer
ZA200901376B (en) Trauma therapy
HK1140675A1 (en) Therapeutic use of diaminophenothiazines
EP2049139A4 (en) Treatment of ras-expressing tumors
HK1147684A1 (en) Targeted radiotherapy
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
GB201001077D0 (en) Viewing of feeds
PT2147122E (en) Enzymatic anticancer therapy
GB0719518D0 (en) Therapy
EP2158002A4 (en) Dual chamber pacemaker
EP1890761A4 (en) Methods of increasing lipolysis
EP2091971A4 (en) Therapeutic targeting of escort proteins
EP2217721A4 (en) Osteoarthritis gene therapy
ZA201001876B (en) Treatment of lung cancer
GB0606660D0 (en) Targeted Therapy
SI2203170T1 (en) NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
GB0600903D0 (en) Treatment of cancer
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
PL380652A1 (en) Grinder of mini-particles
GB0622581D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/04 20060101AFI20120103BHEP

Ipc: C07K 7/04 20060101ALI20120103BHEP

Ipc: A61K 38/10 20060101ALI20120103BHEP

Ipc: C07D 209/38 20060101ALI20120103BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120113

17Q First examination report despatched

Effective date: 20130325

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131204